活血化瘀方联合阿立哌唑治疗精神分裂症患者伴发代谢综合征的临床分析

Clinical Analysis of Huoxue Huayu Recipe Combined with Aripiprazole in Treating Schizophrenic Patients with Metabolic Syndrome

ES评分 0

DOI
刊名
Journal of International Psychiatry
年,卷(期) 2024, 51(3)
作者
作者单位

武汉市优抚医院 ;

摘要
【摘要】 观察活血化瘀方联合阿立哌唑治疗精神分裂症伴发代谢综合征患者的临床疗效和安全性。方法 选取2020年6月至2022年6月期间在本院就诊的60例精神分裂症伴代谢综合征患者,随机分为治疗组和对照组,每组30例,治疗组采用阿立哌唑联合活血化瘀方治疗,对照组采用阿立哌唑西药治疗,治疗时间为3个月。分别在基线期、治疗4周后、8周后、12周后检测两组患者的体质指数(Body Mass Index,BMI)、空腹血糖、血脂水平(甘油三酯和HDL-C)、血液流变学指标(包括全血低切、高切、还原粘度)、简明精神病量表(The Brief Psychiatric Rating Scale, BPRS)总分、阳性和阴性症状量表(Positive and Negative Syndrome Scale,PANSS)总分以及安全性。结果 ① 两组患者在基线时BMI、空腹血糖、甘油三酯和HDL-C、高切变血粘度、低切变血粘度和血浆粘度均无明显差异,治疗组患者在治疗后4周、8周、12周后以上各指标均明显降低,而对照组无明显变化,且治疗组不同时间点均低于对照组(均P<0.05)。② 两组患者在基线时BMI、BPRS总分和PANSS总分均无明显差异,治疗组和对照组患者在治疗后4周、8周、12周后以上各指标均明显降低(均P<0.05),且治疗组不同时间点均低于对照组(均P<0.05)。③ 治疗组和对照组不良反应的发生率分别为20%和16.67%,两组患者不良反应的发生率无明显差异(χ2=0.111,P=0.739)。结论 活血化瘀方联合阿立哌唑治疗精神分裂症伴发代谢综合征患者的临床疗效明确且具有良好的安全性,值得临床进一步推广使用。
Abstract
[Objective] To observe the clinical efficacy and safety of Huoxue Huayu Recipe combined with Aripiprazole in the treatment of schizophrenia with metabolic syndrome. Methods From June 2020 to June 2022, 60 schizophrenic patients with metabolic syndrome who were hospitalized in our hospital were randomly divided into the treatment group and the control group, with 30 cases in each group, The treatment group was treated with Aripiprazole combined with Huoxue Huayu Recipe, and the control group was treated with Aripiprazole for three months. Glucose test Fasting blood sugar, blood lipid level, Hemorheology indicators (including whole blood low shear, high shear, and reduced viscosity), the total score of the Brief Psychiatric Rating Scale (BPRS), the total score of the Positive and Negative Syndrome Scale (PANSS), the body mass index (BMI), and the safety of the patients in the two groups were measured at baseline, 4 weeks after treatment, 8 weeks after treatment, and 12 weeks after treatment. Results ① There were no significant differences in baseline BMI, fasting blood glucose, triglycerides and HDL-C, high shear blood viscosity, low shear blood viscosity, and plasma viscosity between the two groups of patients. The treatment group showed significant reductions in all indicators at 4, 8, and 12 weeks after treatment, while the control group showed no significant changes. The treatment group was lower than the control group at different time points (all P<0.05) There was no significant difference in BMI, BPRS total score, and PANSS total score between the two groups of patients at baseline. The treatment group and control group showed significant reductions in all indicators above 4, 8, and 12 weeks after treatment (all P<0.05), and the treatment group was lower than the control group at different time points (all P<0.05) The incidence of adverse reactions in the treatment group and control group was 20% and 16.67% respectively, and there was no significant difference in the incidence of adverse reactions between the two groups of patients(χ2=0.111, P=0.739).Conclusion Huoxue Huayu Recipe combined with Aripiprazole has clear clinical efficacy and good safety in the treatment of schizophrenia with metabolic syndrome, which is worthy of further clinical promotion.
关键词
活血化瘀方;阿立哌唑;精神分裂症;代谢综合征
KeyWord
Huoxue Huayu Formula; Aripiprazole; Schizophrenia; Metabolic
基金项目
页码 723-727
  • 参考文献
  • 相关文献
  • 引用本文

黄凌霜*. 活血化瘀方联合阿立哌唑治疗精神分裂症患者伴发代谢综合征的临床分析 [J]. 国际精神病学杂志. 2024; 51; (3). 723 - 727.

  • 文献评论

相关学者

相关机构